Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Exclusion Criteria

• •Patients with squamous non-small cell lung carcinoma
• •Serious or non-healing wound, ulcer or bone fracture
• •History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 28 days of day 1 of registration
• •Invasive procedures defined as follows:
• •* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1 registration
• •* Anticipation of need for major surgical procedures during the course of the study
• •* Core biopsy within 7 days prior to day 1 of therapy
• •Patients may not be receiving any other investigational agents
• •Patients with bleeding diathesis (clinical bleeding, prothrombin time \>= 1.5 X upper institutional normal value, INR \>= 1.5, activated partial thromboplastin time aPTT \>= 1.5 X upper institutional normal value), active gastric or duodenal ulcer
• •Uncontrolled systemic vascular hypertension (Systolic blood pressure \> 140 mmHg, Diastolic Blood Pressure \> 90 mmHg)
• •Urine protein should be screened by dipstick or urine analysis; for proteinuria \> 1+ or urine protein:creatinine ratio \> 1.0, 24-hour urine protein should be obtained and the level should be \< 1000 mg for patient enrollment
• •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring parenteral antibiotics on Day 1
• •Patients with clinically significant cardiovascular disease:
• •* History of CVA within 6 months
• •* Myocardial Infarction or unstable angina within 6 months
• •* New York Heart Association Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, unstable angina pectoris
• •* Clinically significant peripheral vascular disease
• •* QTc prolongation \> 500msec or other significant ECG abnormality noted within 14 days of registration
• •* Conditions requiring concurrent use of drugs or biologics with proarrythmic potential; these drugs are prohibited during studies with AZD2171 (refer to appendix V for a listing of these agents)
• •Patients with history of hemoptysis
• •Patients with tumor mass abutting a major vessel
• •Pregnant women are excluded from this study because AZD-2171 is an angiogenesis inhibiting agent with potential teratogenic or abortifacient effects; because of the potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD-2171, breastfeeding should be discontinued if the mother is treated with AZD-2171; these potential risks may also apply to other agents used in this study; women of child-bearing potential and men must agree to use contraception prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately